Patient demographics and baseline characteristics (ITT)
| Characteristic . | Monotherapy (n = 49) . | Combination therapy (n = 72) . |
|---|---|---|
| Age, median (range), y | 60.0 (21-89) | 60.5 (22-85) |
| >65 y, n (%) | 21 (43) | 21 (29) |
| Male, n (%) | 38 (78) | 44 (61) |
| Race, n (%) | ||
| White | 43 (88) | 62 (86) |
| African American | 3 (6) | 6 (8) |
| Asian | 2 (4) | 0 |
| Unknown | 1 (2) | 4 (6) |
| ECOG performance status, n (%) | ||
| 0 | 22 (45) | 28 (39) |
| 1 | 25 (51) | 41 (57) |
| 2 | 1 (2) | 2 (3) |
| Missing | 1 (2) | 1 (1) |
| Prior systemic therapies | ||
| Median (range) | 3 (1-12) | 3 (1-13) |
| Number, n (%) | ||
| 1 | 5 (10) | 10 (14) |
| 2 | 11 (22) | 15 (21) |
| 3 | 11 (22) | 14 (19) |
| 4 | 5 (10) | 12 (17) |
| ≥5 | 17 (35) | 21 (29) |
| Prior radiation, n (%) | 18 (37) | 29 (40) |
| Prior hematopoietic stem cell transplant, n (%) | 15 (31) | 21 (29) |
| Median (range) duration since initial diagnosis, years | 4.1 (0.8-18.0) | 3.2 (0.3-24.1) |
| Lymphoma subtype, n (%) | ||
| NHL | 32 (65) | 50 (69) |
| CLL/SLL | 12 (24) | 1 (1) |
| FL | 8 (16) | 11 (15) |
| MCL | 6 (12) | 0 |
| DLBCL | 2 (4) | 23 (32) |
| GCB | 0 | 9 (13) |
| Non-GCB | 0 | 13 (18) |
| Unknown | 2 (4) | 1 (1) |
| PMBCL | 0 | 2 (3) |
| Transformed NHL histology | 1 (2) | 8 (11) |
| MZL | 2 (4) | 3 (4) |
| Splenic | 1 (2) | 2 (3) |
| Nodal | 1 (2) | 1 (1) |
| WM | 1 (2) | 2 (3) |
| HL | 17 (35) | 22 (31) |
| cHL | 17 (35) | 21 (29) |
| Nodular sclerosis HL | 15 (31) | 18 (25) |
| Mixed-cellularity HL | 2 (4) | 2 (3) |
| Subtype unknown | 0 | 1 (1) |
| NLP HL | 0 | 1 (1) |
| Prior therapies in cHL | ||
| Prior systemic therapies | ||
| Median (range) | 4 (1-12) | 4 (1-13) |
| Number, n (%) | ||
| 1 | 2 (12) | 1 (5) |
| 2 | 0 | 3 (14) |
| 3 | 4 (24) | 4 (19) |
| 4 | 3 (18) | 3 (14) |
| ≥5 | 8 (47) | 10 (48) |
| Prior treatment with brentuximab, n (%) | 14 (82) | 15 (71) |
| Prior radiation, n (%) | 9 (53) | 11 (52) |
| Prior hematopoietic stem cell transplant, n (%) | 11 (65) | 14 (67) |
| Characteristic . | Monotherapy (n = 49) . | Combination therapy (n = 72) . |
|---|---|---|
| Age, median (range), y | 60.0 (21-89) | 60.5 (22-85) |
| >65 y, n (%) | 21 (43) | 21 (29) |
| Male, n (%) | 38 (78) | 44 (61) |
| Race, n (%) | ||
| White | 43 (88) | 62 (86) |
| African American | 3 (6) | 6 (8) |
| Asian | 2 (4) | 0 |
| Unknown | 1 (2) | 4 (6) |
| ECOG performance status, n (%) | ||
| 0 | 22 (45) | 28 (39) |
| 1 | 25 (51) | 41 (57) |
| 2 | 1 (2) | 2 (3) |
| Missing | 1 (2) | 1 (1) |
| Prior systemic therapies | ||
| Median (range) | 3 (1-12) | 3 (1-13) |
| Number, n (%) | ||
| 1 | 5 (10) | 10 (14) |
| 2 | 11 (22) | 15 (21) |
| 3 | 11 (22) | 14 (19) |
| 4 | 5 (10) | 12 (17) |
| ≥5 | 17 (35) | 21 (29) |
| Prior radiation, n (%) | 18 (37) | 29 (40) |
| Prior hematopoietic stem cell transplant, n (%) | 15 (31) | 21 (29) |
| Median (range) duration since initial diagnosis, years | 4.1 (0.8-18.0) | 3.2 (0.3-24.1) |
| Lymphoma subtype, n (%) | ||
| NHL | 32 (65) | 50 (69) |
| CLL/SLL | 12 (24) | 1 (1) |
| FL | 8 (16) | 11 (15) |
| MCL | 6 (12) | 0 |
| DLBCL | 2 (4) | 23 (32) |
| GCB | 0 | 9 (13) |
| Non-GCB | 0 | 13 (18) |
| Unknown | 2 (4) | 1 (1) |
| PMBCL | 0 | 2 (3) |
| Transformed NHL histology | 1 (2) | 8 (11) |
| MZL | 2 (4) | 3 (4) |
| Splenic | 1 (2) | 2 (3) |
| Nodal | 1 (2) | 1 (1) |
| WM | 1 (2) | 2 (3) |
| HL | 17 (35) | 22 (31) |
| cHL | 17 (35) | 21 (29) |
| Nodular sclerosis HL | 15 (31) | 18 (25) |
| Mixed-cellularity HL | 2 (4) | 2 (3) |
| Subtype unknown | 0 | 1 (1) |
| NLP HL | 0 | 1 (1) |
| Prior therapies in cHL | ||
| Prior systemic therapies | ||
| Median (range) | 4 (1-12) | 4 (1-13) |
| Number, n (%) | ||
| 1 | 2 (12) | 1 (5) |
| 2 | 0 | 3 (14) |
| 3 | 4 (24) | 4 (19) |
| 4 | 3 (18) | 3 (14) |
| ≥5 | 8 (47) | 10 (48) |
| Prior treatment with brentuximab, n (%) | 14 (82) | 15 (71) |
| Prior radiation, n (%) | 9 (53) | 11 (52) |
| Prior hematopoietic stem cell transplant, n (%) | 11 (65) | 14 (67) |
CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL, follicular lymphoma; ITT, intent-to-treat; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NA, not applicable; NLP HL, nodular lymphocytic-predominant Hodgkin lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; WM, Waldenström macroglobulinemia.